Enfusion Valuation
| ENFN Stock | USD 11.07 0.02 0.18% |
At this time, the firm appears to be fairly valued. Enfusion shows a prevailing Real Value of $11.15 per share. The current price of the firm is $11.07. Our model computes the value of Enfusion from reviewing the firm fundamentals such as Shares Outstanding of 94.8 M, profit margin of 0.01 %, and Current Valuation of 1.02 B as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Enfusion's valuation include:
Price Book 14.3587 | Enterprise Value | Enterprise Value Ebitda 56.7975 | Price Sales 5.2148 | Forward PE 49.0196 |
Fairly Valued
Today
Please note that Enfusion's price fluctuation is not too volatile at this time. Calculation of the real value of Enfusion is based on 3 months time horizon. Increasing Enfusion's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enfusion is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enfusion Stock. However, Enfusion's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.07 | Real 11.15 | Target 9.89 | Hype 11.09 | Naive 10.85 |
The intrinsic value of Enfusion's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enfusion's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enfusion helps investors to forecast how Enfusion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enfusion more accurately as focusing exclusively on Enfusion's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Enfusion's intrinsic value based on its ongoing forecasts of Enfusion's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Enfusion's closest peers.
Enfusion Cash |
|
Enfusion Valuation Trend
Knowing Enfusion's actual value is paramount for traders when making sound investment determinations. Using both Enfusion's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Enfusion Revenue by Product
Enfusion Total Value Analysis
Enfusion is currently forecasted to have valuation of 1.02 B with market capitalization of 1.05 B, debt of 20.31 M, and cash on hands of 56.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Enfusion fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.02 B | 1.05 B | 20.31 M | 56.56 M |
Enfusion Investor Information
About 97.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.35. Enfusion had not issued any dividends in recent years. Based on the analysis of Enfusion's profitability, liquidity, and operating efficiency, Enfusion is performing exceptionally good at the present time. It has a great chance to report excellent financial results in April.Enfusion Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enfusion has an asset utilization ratio of 140.73 percent. This suggests that the Company is making $1.41 for each dollar of assets. An increasing asset utilization means that Enfusion is more efficient with each dollar of assets it utilizes for everyday operations.Enfusion Ownership Allocation
Enfusion holds a total of 94.8 Million outstanding shares. The majority of Enfusion outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enfusion to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enfusion. Please pay attention to any change in the institutional holdings of Enfusion as this could imply that something significant has changed or is about to change at the company. Also note that almost one million five hundred sixty-four thousand two hundred thirty-five invesors are currently shorting Enfusion expressing very little confidence in its future performance.Enfusion Profitability Analysis
The company reported the previous year's revenue of 201.61 M. Net Income was 3.92 M with profit before overhead, payroll, taxes, and interest of 136.74 M.About Enfusion Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Enfusion. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Enfusion based exclusively on its fundamental and basic technical indicators. By analyzing Enfusion's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Enfusion's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enfusion. We calculate exposure to Enfusion's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enfusion's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 136.7 M | 98.5 M | |
| Pretax Profit Margin | 0.04 | 0.04 | |
| Operating Profit Margin | 0.03 | 0.03 | |
| Net Profit Margin | 0.01 | 0.01 | |
| Gross Profit Margin | 0.68 | 0.77 |
Enfusion Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 129.6 M | |
| Quarterly Earnings Growth Y O Y | -0.818 | |
| Forward Price Earnings | 49.0196 |
Enfusion Current Valuation Indicators
Enfusion's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Enfusion's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Enfusion, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Enfusion's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Enfusion's worth.When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share 0.03 | Revenue Per Share | Quarterly Revenue Growth 0.139 | Return On Assets |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.